Genscript Biotech Corp
HKEX:1548
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
8.97
19.28
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Operating Margin
Genscript Biotech Corp
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CN |
|
Genscript Biotech Corp
HKEX:1548
|
27.2B HKD |
61%
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
13%
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
212.4B USD |
18%
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
157.2B USD |
19%
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
36.1B CHF |
15%
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
38.8B USD |
21%
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
37.7B USD |
14%
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
259.1B CNY |
30%
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
45.1T KRW |
37%
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
28.3B USD |
28%
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
19.8B EUR |
17%
|
Genscript Biotech Corp
Glance View
In the dynamic world of biotechnology, GenScript Biotech Corp. has carved out a significant niche, positioning itself as a global leader specializing in life science research, biologics development, and other burgeoning areas like cell therapy. Founded in 2002, the company has grown rapidly, fueled by innovation and a relentless focus on quality. GenScript operates through several key segments, including life sciences, biologics contract development and manufacturing organization (CDMO), industrial synthetic products, and cell therapy. This multi-pronged structure enables the firm to cater to diverse sectors, from academic research institutions that rely on its reagents and consumables, to pharmaceutical companies seeking robust biologics solutions. Their life sciences offerings, particularly custom gene synthesis—where they create bespoke DNA sequences upon request—help scientists chase breakthroughs in genetics and molecular biology, underpinning much of the company's revenue stream. From a business perspective, GenScript’s model thrives on providing a combination of high-quality products and services that streamline the development of medications and therapies. At the heart of their success is a focus on technological advancements and collaborative partnerships. The biologics CDMO segment, for instance, allows pharmaceutical firms to outsource critical drug development processes, facilitating enhanced flexibility and efficiency in drug production cycles. Meanwhile, in the emerging field of cell therapies, GenScript is leveraging its technical prowess to offer cutting-edge development platforms, including CAR-T therapy, which is known for its potential in fighting cancer. Through its strategic initiatives and investments in R&D, GenScript not only ensures a steady flow of income across its operational segments but also fosters long-term growth by continuously widening its scientific and technical capabilities.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Genscript Biotech Corp's most recent financial statements, the company has Operating Margin of 61%.